Physician profile
Rahal Ehsan
NPI 1710553268
$863.02
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $308 · 2023: $353 · 2024: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $141.43 | 2023-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $130.47 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $89.19 | 2022-2023 | Xarelto |
| Pfizer INC. | $61.87 | 2023 | |
| Amgen INC. | $55.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.58 | 2022 | |
| Merck Sharp & Dohme LLC | $45.42 | 2022-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $34.27 | 2022-2023 | Camzyos |
| Qol Medical, LLC | $28.95 | 2023 | Sucraid |
| Kiniksa Pharmaceuticals, Ltd. | $27.78 | 2022 | |
| Daiichi Sankyo INC. | $25.01 | 2022 | |
| Alcresta Therapeutics, INC. | $24.82 | 2024 | Relizorb |
| Astrazeneca Pharmaceuticals Lp | $23.26 | 2023 | Farxiga |
| Evoke Pharma, INC. | $22.08 | 2023 | Gimoti |
| Esperion Therapeutics, INC. | $21.66 | 2024 | Nexletol |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.57 | 2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $18.81 | 2023 | Ocaliva |
| Kiniksa Pharmaceuticals International, Plc | $18.11 | 2024 | Arcalyst |
| Lilly USA, LLC | $17.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahal Ehsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.